Ten years ago, Congress passed a law intended to penalize chief executive officers whose companies shift their legal addresses to tax havens.
Valeant Pharmaceuticals International Inc.’s merger talks with Actavis Inc. have stalled because of a disagreement on price, according to people familiar with the matter.
Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.
Actavis Inc.’s $5 billion deal to buy Warner Chilcott Plc brings in a new stable of brand-name women’s health drugs. It also comes with headquarters relocated to Ireland and lower taxes for the combined company.